{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_004770.3:c.2053G>A",
          "cDNA Change": {
            "transcript": "NM_004770.3",
            "ref": "G",
            "alt": "A",
            "position": "2053"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "A",
            "position": "684"
          },
          "Description in input context": "This variant, LRRK2 c.2053G>A (p.R684A), has been associated with increased kinase activity."
        },
        {
          "HGVS": "NM_004770.3:c.1184A>G",
          "cDNA Change": {
            "transcript": "NM_004770.3",
            "ref": "A",
            "alt": "G",
            "position": "1184"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "G",
            "position": "395"
          },
          "Description in input context": "Variant LRRK2 c.1184A>G (p.D395G) has been shown to alter protein conformation."
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's Disease",
    "MONDO": "MONDO:0003957"
  },
  "Experiment Method": [
    {
      "Assay Method": "Kinase Activity Assay",
      "Material used": {
        "Material Source": "Cell Line",
        "Material Name": "HEK293",
        "Description": "Recombinant LRRK2 protein and HEK293 cells were used to study kinase activity."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_004770.3:c.2053G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased Kinase Activity",
          "Result Description": "The kinase activity of LRRK2 with variant c.2053G>A was increased by 2-fold compared to wild type."
        },
        {
          "Variant": "NM_004770.3:c.1184A>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Altered Conformation",
          "Result Description": "The protein conformation of LRRK2 with variant c.1184A>G was altered compared to wildtype. "
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed for each variant."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was run in triplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 cDNA was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "No",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "No",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA with post-hoc Tukey's test was used for statistical analysis."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Kinase activity within the range of 0.8-1.2 relative to control.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Kinase activity outside the range of 0.8-1.2 relative to control.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}